Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027

Whitehawk Therapeutics CEO Dave Lennon outlined the company's strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believes can support broad activity across multiple tumor types. Company reset and runway Lennon said the